Beneficial impact of spironolactone in diabetic nephropathy.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Kidney International

• Publication date

  2005-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/J.1523-1755.2005.00756.XPMID 16316360
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy.

  2005cited by this paper
• Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients: Losartan Intervention for Endpoint Reduction in Hypertension Study

  2005cited by this paper
• Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats.

  2004cited by this paper
• The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study

  2004cited by this paper
• Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.

  2004cited by this paper
• What is the role of albumin in proteinuric glomerulopathies?

  2004cited by this paper
• Aldosterone escape during blockade of the renin–angiotensin–aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate

  2004influential reference
• Spironolactone impairs endothelial function and heart rate variability in patients with Type 2 diabetes

  2004cited by this paper
• Albuminuria, a Therapeutic Target for Cardiovascular Protection in Type 2 Diabetic Patients With Nephropathy

  2004cited by this paper
• Aldosterone induces contraction of the resistance arteries in man.

  2003cited by this paper
• Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy.

  2003cited by this paper
• Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial.

  2003cited by this paper
• Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy.

  2003cited by this paper
• Effectiveness of Aldosterone Blockade in Patients With Diabetic Nephropathy

  2003influential reference
• Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats.

  2003cited by this paper
• Nongenomic vascular action of aldosterone in the glomerular microcirculation.

  2003cited by this paper
• Pathophysiology of proteinuria.

  2003cited by this paper
• Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy.

  2002cited by this paper
• Aldosterone as a Determinant of Cardiovascular and Renal Dysfunction

  2001cited by this paper
• Aldosterone in progressive renal disease.

  2001cited by this paper
• Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype.

  2001influential reference
• Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease.

  2001cited by this paper
• Aldosterone and the hypertensive kidney: its emerging role as a mediator of progressive renal dysfunction: a paradigm shift

  2001cited by this paper
• Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications.

  2001cited by this paper
• Glomerular permselectivity in early stages of overt diabetic nephropathy.

  2000cited by this paper
• Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

  2000cited by this paper
• Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

  2000cited by this paper
• The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

  1999cited by this paper
• Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators.

  1999cited by this paper
• Glomerular hypertension as one cause of albuminuria in Type II diabetic patients

  1999cited by this paper
• Depression as a risk factor for ischaemic heart disease in men: population based case-control study

  1998cited by this paper
• Promotion, prediction and prevention of progression of nephropathy in Type 1 diabetes mellitus

  1998cited by this paper
• Promotion, prediction, and prevention of progression in diabetic nephropathy.

  1998cited by this paper
• Impaired autoregulation of GFR in hypertensive non-insulin dependent diabetic patients.

  1997cited by this paper
• Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]).

  1996cited by this paper
• Role of aldosterone in the remnant kidney model in the rat.

  1996cited by this paper
• Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment

  1994cited by this paper
• Mechanisms of enhanced angiotensin II–stimulated signal transduction in vascular smooth muscle by aldosterone

  1994cited by this paper
• Vasodilation to acetylcholine in primary and secondary forms of human hypertension.

  1993cited by this paper
• Effect of aldosterone on vascular angiotensin II receptors in the rat.

  1985cited by this paper
• Hemodynamic basis for glomerular injury in rats with desoxycorticosterone-salt hypertension.

  1984cited by this paper
• Impaired autoregulation of glomerular filtration rate in Type 1 (insulin-dependent) diabetic patients with nephropathy

  1984cited by this paper
• Asynchronous changes in prorenin and renin secretion after captopril in patients with renal artery stenosis.

  1983cited by this paper
• Catecholamine-mediated constrictor effects of aldosterone on vascular smooth muscle.

  1982cited by this paper
• Molecular basis of proteinuria of glomerular origin.

  1978cited by this paper
• Selection of routine method for determination of glomerular filtration rate in adult patients.

  1976cited by this paper
• A simple method for the determination of glomerular filtration rate.

  1972cited by this paper
• Downloaded from http://hyper.ahajournals.org / by guest on February 21, 2013Role of Aldosterone in Renal Vascular Injury in Stroke-Prone Hypertensive Rats

  year unknowncited by this paper

• The Role of Aldosterone in Vascular Permeability in Diabetes

  2026cites this paper
• Efficacy and Safety of Low‐Dose Spironolactone in Management of Diabetic Kidney Disease in a Real‐World Setting

  2025cites this paper
• Kidney Disease: The Forgotten Legacy of Type 1 Diabetes.

  2025cites this paper
• Real-world use of finerenone in diabetic kidney disease: eGFR slope analysis with exploratory data on prior MRA use

  2025cites this paper
• Long-term Impact of Alpha-blockers on Renal Function - A Systematic Review and Meta-analysis.

  2025cites this paper
• Finerenone in type 1 diabetes and chronic kidney disease: short-term efficacy and safety insights

  2025cites this paper
• Advancing kidney protection in type 1 diabetes: insights from emerging therapies in type 2 diabetes and chronic kidney disease

  2025cites this paper
• The glomerular endothelial glycocalyx as a therapeutic target in proteinuric kidney disease

  2025cites this paper
• A Systematic Review and Meta-Analysis: Long-Term Impact of Alpha-Blockers on Renal Function

  2025cites this paper
• The association between mineralocorticoid receptor antagonist use and diabetes occurrence and progression: A systematic review and meta-analysis.

  2025cites this paper
• Association between mineralocorticoid receptor antagonists and kidney harm: A systematic review and meta‐analysis of randomized controlled trials

  2024cites this paper
• The Mineralocorticoid Receptors in diabetic kidney disease.

  2024cites this paper
• Efficacy and safety of nonsteroidal mineralocorticoid receptor antagonists for renal and cardiovascular outcomes in patients with chronic kidney disease: a meta-analysis of randomized clinical trials

  2024cites this paper
• Normoalbuminuria—is it normal? The association of urinary albumin within the ‘normoalbuminuric’ range with adverse cardiovascular and mortality outcomes: A systematic review and meta‐analysis

  2024cites this paper
• Mineralocorticoid Receptor Antagonists for Preventing Chronic Kidney Disease Progression: Current Evidence and Future Challenges

  2023cites this paper
• Renin-independent aldosteronism and chronic kidney disease in diabetes: Observational and Mendelian randomization analyses.

  2023cites this paper
• Additive effects of dapagliflozin and finerenone on albuminuria in non-diabetic CKD: an open-label randomized clinical trial

  2023cites this paper
• Effects of Mineralocorticoid Receptor Antagonists for Chronic Kidney Disease: A Systemic Review and Meta-Analysis

  2023cites this paper
• Therapieoptionen bei diabetischer Nephropathie

  2023cites this paper
• Chronic kidney disease in type 1 diabetes: translation of novel type 2 diabetes therapeutics to individuals with type 1 diabetes

  2023cites this paper
• Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trial.

  2023cites this paper
• Mineralocorticoid receptor antagonist use in chronic kidney disease with type 2 diabetes: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA)

  2023cites this paper
• A Narrative Review of Signaling Pathway and Treatment Options for Diabetic Nephropathy.

  2023cites this paper
• Renoprotective Effects of Mineralocorticoid Receptor Antagonists Against Diabetic Kidney Disease

  2023cites this paper
• Endotrophin as a risk marker of mortality and kidney complications in a type 1 diabetes cohort

  2023cites this paper
• Ameliorating Cardiovascular Risk in Patients with Type 2 Diabetes.

  2022cites this paper
• Efficacy and safety of a low-sodium diet and spironolactone in patients with stage 1-3a chronic kidney disease: a pilot study

  2022cites this paper
• Aldosterone, Mineralocorticoid Receptor Activation, and CKD: A Review of Evolving Treatment Paradigms.

  2022cites this paper
• A Strategic Investigation on Diabetic Nephropathy; Its Conceptual Model and clinical Manifestations: A Review.

  2022cites this paper
• Role of Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease

  2022cites this paper
• Diabetes Mellitus and Heart Failure With Preserved Ejection Fraction: Role of Obesity

  2022cites this paper
• A Compressive Review on Novel Molecular Target of Diabetic Nephropathy

  2022cites this paper
• Clinical perspective-evolving evidence of mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes.

  2022cites this paper
• Cardiovascular and Renal Outcomes with Finerenone, a Selective Mineralocorticoid Receptor Antagonist

  2022cites this paper
• Clinical implications and guidelines for CKD in type 2 diabetes.

  2022cites this paper
• Serum potassium changes due to concomitant ACEI/ARB and spironolactone therapy: A systematic review and meta-analysis

  2021cites this paper
• Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease.

  2021cites this paper
• Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease

  2021cites this paper
• Finerenon

  2021cites this paper
• Cardiovascular and kidney outcomes of spironolactone or eplerenone in combination with ACEI/ARBs in patients with diabetic kidney disease

  2021cites this paper
• Mineralocorticoid receptor antagonists in diabetic kidney disease — mechanistic and therapeutic effects

  2021cites this paper
• The Forgotten Antiproteinuric Properties of Diuretics

  2021cites this paper
• Efficacy and safety of finerenone in patients with chronic kidney disease: a systematic review with meta-analysis and trial sequential analysis.

  2021cites this paper
• A systematic review and meta-analysis of effects of spironolactone on blood pressure, glucose, lipids, renal function, fibrosis and inflammation in patients with hypertension and diabetes

  2021influential citation
• Efficacy and safety of dual vs single renin–angiotensin–aldosterone system blockade in chronic kidney disease

  2021cites this paper
• Mineralocorticoid receptor antagonists use in patients with heart failure and impaired renal function

  2021cites this paper
• A Review on Diabetic Nephropathy Disease : Risk Factors and Complications D Review

  2020cites this paper
• Pharmacotherapy of hypertension in patients with pre-dialysis chronic kidney disease

  2020cites this paper
• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease.

  2020cites this paper
• Hyperkalemia and Acute Kidney Injury with Spironolactone Use Among Patients with Heart Failure.

  2020cites this paper
• Baseline urinary metabolites predict albuminuria response to spironolactone in type 2 diabetes.

  2020cites this paper
• Management of hyperkalemia during treatment with mineralocorticoid receptor blockers: findings from esaxerenone

  2020cites this paper
• Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial.

  2020cites this paper
• Chronic kidney disease in type 2 diabetes: Implications for managing glycaemic control, cardiovascular and renal risk

  2020influential citation
• Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease: a systematic review and meta-analysis of randomized controlled trials.

  2019cites this paper
• Diabetic complication prediction using a similarity-enhanced latent Dirichlet allocation model

  2019cites this paper
• Spironolactone alleviates diabetic nephropathy through promoting autophagy in podocytes

  2019cites this paper
• Efficacy and safety of mineralocorticoid receptor antagonists with ACEI/ARB treatment for diabetic nephropathy: A meta‐analysis

  2019cites this paper
• Does the temporary decrease in the estimated glomerular filtration rate (eGFR) after initiation of mineralocorticoid receptor (MR) antagonist treatment lead to a long-term renal protective effect?

  2019cites this paper
• Captopril and Spironolactone Can Attenuate Diabetic Nephropathy in Wistar Rats by Targeting microRNA-192 and microRNA-29a/b/c

  2019cites this paper
• Mineralocorticoid Antagonism and Diabetic Kidney Disease

  2019cites this paper
• Comparison of Outcomes in Patients With Diabetes Mellitus Treated With Versus Without Insulin + Heart Failure With Preserved Left Ventricular Ejection Fraction (from the TOPCAT Study).

  2019cites this paper
• Boosting the Limited Use of Mineralocorticoid Receptor Antagonists Through New Agents for Hyperkalemia.

  2019cites this paper
• Efficacy and Safety of Dual Blockade of the Renin–Angiotensin–Aldosterone System in Diabetic Kidney Disease: A Meta-Analysis

  2019cites this paper
• Mineralocorticoid Receptor Antagonists for Nephroprotection: Current Evidence and Future Perspectives.

  2019cites this paper
• Future and Novel Compounds in the Treatment of Diabetic Nephropathy

  2018cites this paper
• Prognosis and treatment of diabetic nephropathy: Recent advances and perspectives.

  2018cites this paper
• Clinical effect of mineralocorticoid receptor antagonist combined with angiotensin receptor blocker or angiotensin converting enzyme inhibitor in treating diabetic nephropathy : a systematic review and meta-analysis

  2018cites this paper
• Efficacy of Aldosterone Antagonist with RAAS Blockade in Patients with Diabetic Kidney Disease

  2018cites this paper
• Treatment Goals in Diabetic Nephropathy

  2018cites this paper
• Novel therapies for diabetic kidney disease.

  2018cites this paper
• Novel avenues for drug discovery in diabetic kidney disease

  2018cites this paper
• Rôle de la Neutrophil Gelatinase-Associated Lipocalin dans les effets cardiovasculaires et rénaux de l'activation du récepteur minéralocorticoïde. Spécificité et mécanismes d’action

  2017cites this paper
• Glucose 6-phosphate dehydrogenase and the kidney

  2017cites this paper
• Primary aldosteronism: a common cause of resistant hypertension

  2017cites this paper
• Effects of mineralocorticoid receptor antagonists on the progression of diabetic nephropathy

  2017cites this paper
• A systematic review and meta-analysis of the impact of mineralocorticoid receptor antagonists on glucose homeostasis

  2017cites this paper
• A Novel Aldosterone Antagonist Limits Renal Injury in 5/6 Nephrectomy

  2017cites this paper
• Predicting albuminuria response to spironolactone treatment with urinary proteomics in patients with type 2 diabetes and hypertension

  2017cites this paper
• A review of chemical therapies for treating diabetic hypertension

  2017cites this paper
• Effect of hydrochlorothiazide and spironolactone on reducing proteinuria among patients with diabetic nephropathy treated by angiotensin converting enzyme inhibitors

  2016cites this paper
• Chapter 54 – Diabetic Nephropathy

  2016cites this paper
• Inhibiting MicroRNA-503 and MicroRNA-181d with Losartan Ameliorates Diabetic Nephropathy in KKAy Mice

  2016cites this paper
• Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis

  2016cites this paper
• Dual Blockade of the Renin-angiotensin-aldosterone System in Type 2 Diabetic Kidney Disease

  2016cites this paper
• Assessment of Spironolactone Effects on the Prevention of Progression of Proteinuria in Chronic Kidney Diseases

  2016cites this paper
• Cardiovascular actions of mineralocorticoid receptor antagonists in patients with chronic kidney disease: A systematic review and meta-analysis of randomized trials

  2015cites this paper
• Twenty years after ACEIs and ARBs : Emerging Treatment Strategies 1 for Diabetic Nephropathy 2 3

  2015cites this paper
• Low Dose Irbesartan Has a Renoprotective Effect as High Dose Ramipril in Diabetic Rats Treated with Insulin

  2015cites this paper
• Impact of Chronic Kidney Disease and Diabetes Mellitus on Choice of Renin Angiotensin System-Inhibitors in Patients with Hypertension and Heart Failure

  2015cites this paper
• Twenty years after ACEIs and ARBs: emerging treatment strategies for diabetic nephropathy.

  2015cites this paper
• Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: a multicenter, randomized clinical trial

  2015cites this paper
• Finerenone: third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease

  2015cites this paper
• The role of aldosterone antagonism agents in diabetic kidney disease.

  2015cites this paper
• Evaluation of spironolactone plus hydrochlorothiazide in reducing proteinuria in type 2 diabetic nephropathy

  2015cites this paper
• The necessity and effectiveness of mineralocorticoid receptor antagonist in the treatment of diabetic nephropathy

  2015cites this paper
• Screening and treatment by the primary care provider of common diabetes complications.

  2015cites this paper
• Spironolactone Add-on for Preventing or Slowing the Progression of Diabetic Nephropathy: A Meta-analysis.

  2015cites this paper
• Inhibition of RAS in diabetic nephropathy

  2015cites this paper
• A diabéteszes és iszkémiás vesekárosodás patomechanizmusának vizsgálata és új kezelési lehetőségei

  2014cites this paper